April 9, 2008 - Echo Therapeutics (OTC Bulletin Board: ECTE) announced positive results from its human feasibility study of the Prelude(TM) SkinPrep System, Echo's next-generation, needle-free, non-invasive skin permeation medium for its Symphony(TM) tCGM System, a novel transdermal continuous glucose monitoring (tCGM) system in development for diabetes home use and hospital critical care markets. Prelude incorporates Echo's patented skin permeation control feedback technology into a comfortable, wireless, hand-held device used to prepare a small area of the skin for the non-invasive, biosensor and monitoring components of its Symphony tCGM system. Results of the feasibility study on healthy subjects demonstrate that Prelude safely and effectively permeated the skin so that the Symphony tCGM System could continuously monitor blood glucose levels reliably over a 24-hour period. Echo plans to use Prelude in the remaining pilot and pivotal clinical studies necessary to commercialize the Symphony tCGM System, including clinical studies scheduled to begin in the second quarter of this year... [PDF] Echo Therapeutics' Press Release -
Tuesday, April 29, 2008
Echo : Prelude SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony Transdermal Continuous Glucose Monitoring System
April 9, 2008 - Echo Therapeutics (OTC Bulletin Board: ECTE) announced positive results from its human feasibility study of the Prelude(TM) SkinPrep System, Echo's next-generation, needle-free, non-invasive skin permeation medium for its Symphony(TM) tCGM System, a novel transdermal continuous glucose monitoring (tCGM) system in development for diabetes home use and hospital critical care markets. Prelude incorporates Echo's patented skin permeation control feedback technology into a comfortable, wireless, hand-held device used to prepare a small area of the skin for the non-invasive, biosensor and monitoring components of its Symphony tCGM system. Results of the feasibility study on healthy subjects demonstrate that Prelude safely and effectively permeated the skin so that the Symphony tCGM System could continuously monitor blood glucose levels reliably over a 24-hour period. Echo plans to use Prelude in the remaining pilot and pivotal clinical studies necessary to commercialize the Symphony tCGM System, including clinical studies scheduled to begin in the second quarter of this year... [PDF] Echo Therapeutics' Press Release -
